STOCK TITAN
  1. Home
  2. News
  3. ADAG

Adagene Inc - ADAG STOCK NEWS

Welcome to our dedicated news page for Adagene (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adagene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adagene's position in the market.

News
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Adagene Inc. reports strong financial results for 2023, highlighting the success of its masked anti-CTLA-4 SAFEbody ADG126 in treating metastatic colorectal cancer. The company's cash balance of $110 million supports operations until 2026. Clinical data shows promising results in MSS CRC patients, with a focus on higher dosing and combination therapies. Collaborations with Exelixis and Sanofi demonstrate the versatility of Adagene's platform. Positive pipeline developments include favorable safety profiles for ADG116 and ADG206, with ongoing clinical trials and potential for further expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Rhea-AI Summary
Adagene Inc. appoints global oncology expert Dr. Heinz-Josef Lenz to its Scientific and Strategic Advisory Board. Dr. Lenz emphasizes the potential of anti-CTLA-4 therapy in treating microsatellite stable colorectal cancer, highlighting the promising results of ADG126 in combination with pembrolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
management
-
News
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
Rhea-AI Summary
Adagene Inc. announces participation in the Leerink Partners Global Biopharma Conference 2024 to provide an update on its anti-CTLA-4 SAFEbody® ADG126 therapy, with key milestones for 2024. The Chairman, CEO, and President of R&D will present at the conference on March 12 in Miami, Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
conferences
News
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Rhea-AI Summary
Adagene Inc. announced progress in the clinical collaboration development program for its anti-CTLA-4 SAFEbody, ADG126, in combination with Merck & Co.'s anti-PD-1 therapy, KEYTRUDA, for patients with metastatic microsatellite-stable colorectal cancer. The company completed the enrollment of 12 additional patients in the ongoing phase 2 dose expansion cohort, plans to evaluate 20 mg/kg loading doses of ADG126, and has received clearance from China’s Center for Drug Evaluation to initiate clinical evaluation of ADG126 in combination with pembrolizumab. Data from the ongoing clinical trial is anticipated throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
-
News
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Rhea-AI Summary
Adagene Inc. announced promising clinical data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium. The data from the first tranche of MSS CRC patients treated with ADG126 showed clinical benefit, with preliminary survival analysis indicating best-in-class median progression-free survival (PFS) of seven months. The company also revealed plans for additional data from these patients throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
-
News
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Rhea-AI Summary
Adagene Inc. (Nasdaq: ADAG) announced interim results in MSS CRC suggesting that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses, overcoming safety-limited efficacy challenges. The poster presentation at the ASCO 2024 Gastrointestinal Cancers Symposium will feature results of a phase 1b/2 study of ADG126 in combination with pembrolizumab in patients with metastatic microsatellite-stable colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences
News
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
Rhea-AI Summary
Adagene Inc. presented new data on its anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data demonstrated that ADG126 is effective at targeting CTLA-4 within the tumor microenvironment, resulting in a wider therapeutic index compared to ipilimumab when combined with anti-PD-1 therapies. The optimal dose of ADG126 at 10 mg/kg every three weeks plus pembrolizumab showed dose-dependent efficacy without a significant increase in treatment-related adverse events. A clinical case example showed a confirmed partial response in a patient with advanced/metastatic MSS CRC. ADG126 may provide greater clinical benefit than ipilimumab in combination with anti-PD-1 in both 'hot' and 'cold' tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
none
-
News
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Rhea-AI Summary
Adagene to present poster at SITC 38th Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
none
-
News
Adagene to Present at Investor and Scientific Conferences in September
Rhea-AI Summary
Adagene Inc. to participate in investor and scientific conferences, including SITC webinar on September 22
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences
News
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
Rhea-AI Summary
Adagene reports strong efficacy signal in MSS CRC phase 2 study for SAFEbody ADG126 in combination with pembrolizumab at 10 mg/kg every three weeks dosing regimen
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.25%
Tags
earnings
Stock ADAG logo
Adagene Inc

Nasdaq:ADAG

ADAG Rankings

#4117 Ranked by Market Cap
#384 Ranked by Stock Gains
N/A Ranked by Dividends

ADAG Stock Data

119.22M
12.99M
4.19%
16.13%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Suzhou

About ADAG

adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.